These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8103618)

  • 21. Parallels between neuroleptic effects and lethargic encephalitis: the production of dyskinesias and cognitive disorders.
    Breggin PR
    Brain Cogn; 1993 Sep; 23(1):8-27. PubMed ID: 8105824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Historical perspective on movement disorders.
    Friedman JH
    J Clin Psychiatry; 2004; 65 Suppl 9():3-8. PubMed ID: 15189105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Late dyskinesias. Clinical aspects, pathophysiology, therapy].
    Brücher K
    Dtsch Med Wochenschr; 1984 Oct; 109(40):1533-7. PubMed ID: 6148229
    [No Abstract]   [Full Text] [Related]  

  • 24. Neuroleptic-induced reinnervation sprouting in the central nervous system (a model for the development of tardive dyskinesia and supersensitivity psychosis).
    Staton RD; Brumback RA
    J Clin Psychiatry; 1980 Dec; 41(12 Pt 1):427-8. PubMed ID: 6108320
    [No Abstract]   [Full Text] [Related]  

  • 25. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy.
    Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH
    Am J Ment Retard; 1996 Sep; 101(2):118-29. PubMed ID: 8883667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia.
    Bsoul SA; Terezhalmy GT; Riley CK; Moore WS
    Quintessence Int; 2002 Apr; 33(4):326-7. PubMed ID: 11989382
    [No Abstract]   [Full Text] [Related]  

  • 27. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyskinesia induced by long-term treatment with antipsychotic drugs: involvement of pre- and postsynaptic dopaminergic mechanisms.
    Engel J; Liljequist S; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():387-95. PubMed ID: 6104913
    [No Abstract]   [Full Text] [Related]  

  • 29. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard.
    Loonen AJ; van Praag HM
    J Clin Psychopharmacol; 2007 Oct; 27(5):423-30. PubMed ID: 17873670
    [No Abstract]   [Full Text] [Related]  

  • 33. Stimulants and neuroleptic withdrawal dyskinesia.
    Connor DF
    J Am Acad Child Adolesc Psychiatry; 1998 Mar; 37(3):247-8. PubMed ID: 9519625
    [No Abstract]   [Full Text] [Related]  

  • 34. Pelvic dyskinesia with an outstanding response to tetrabenazine.
    Alentorn A; Palasí A; Campdelacreu J; Bruna J; Calopa M; Rubio F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):847-8. PubMed ID: 19348867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurological complications of psychiatric drugs: clinical features and management.
    Haddad PM; Dursun SM
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():15-26. PubMed ID: 18098217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia.
    Pourcher E; Cohen H; Cohen D; Baruch P; Bouchard RH
    Brain Cogn; 1993 Sep; 23(1):81-7. PubMed ID: 8105825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic-induced movement disorders - forgotten but not gone.
    Weiden PJ
    Acta Psychiatr Scand; 2008 Jun; 117(6):401-2. PubMed ID: 18479315
    [No Abstract]   [Full Text] [Related]  

  • 38. Oculogyric crisis with exacerbation of psychosis: Possible mechanism and clinical implications.
    Thomas N; Sankar SS; Braganza D; Jayakrishnan S
    Neurosci Lett; 2009 Feb; 451(1):50-1. PubMed ID: 19121367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuroleptic-induced respiratory dyskinesia. Apropos of a case].
    Rubio Esteban G; Vargas Núñez JA; Iruela Cuadrado LM; García Guijo C
    Med Clin (Barc); 1988 Dec; 91(19):758. PubMed ID: 2907075
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-induced movement disorders.
    Powers JM
    Ariz Med; 1983 Jul; 40(7):464-7. PubMed ID: 6138016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.